WebDoctor Encyclopedia

Genitourinary

Urachal carcinoma

Urachal carcinoma is a rare cancer that grows from the urachus, a leftover tube between the top of the bladder and the belly button. It is usually a mucus-producing adenocarcinoma and is treated with partial bladder removal.

Medically reviewed Last reviewed October 27, 2026

What is urachal carcinoma?

Urachal carcinoma is a rare cancer that starts in the urachus, a small tube-like structure left over from development before birth.

In an unborn baby, the urachus connects the top of the bladder to the umbilical cord. It normally closes and shrinks into a fibrous cord, called the median umbilical ligament, that runs from the bladder to the belly button. Small remnants of the lining can remain, and in rare cases a cancer develops from them.

Most urachal cancers are adenocarcinomas, which are glandular cancers that often produce mucus. They usually grow at the dome (top) of the bladder and can extend upwards towards the belly button.

Urachal carcinoma is very different from the common type of bladder cancer, urothelial carcinoma. It tends to affect younger people, often looks like a bowel cancer under the microscope and is treated differently (Szarvas et al., 2016).

1. Key facts at a glance

Feature Details
Type of cancer Usually adenocarcinoma arising from the urachal remnant
How common Very rare; well under 1% of bladder cancers (Olah et al., 2024)
Typical age Median about 50-55; younger than most bladder cancers
Sex Somewhat more common in men
Main site Dome of the bladder and the tissue above it towards the belly button
Main symptom Blood in the urine; sometimes mucus in the urine
Main treatment Partial removal of the bladder with the urachus and belly button
Outlook About half of patients survive 5 years; much better if the cancer is confined and fully removed

2. Causes and risk factors

The cause of urachal carcinoma is not known. Unlike urothelial bladder cancer, it is not strongly linked with smoking or chemical exposure.

Factor Notes
Urachal remnant Everyone has one, but cancer develops from it only very rarely
Age Most patients are between 40 and 70
Sex Men are affected slightly more often
Smoking Possible but weak link; less important than in other bladder cancers

Urachal carcinoma is not inherited. A urachal cyst or other remnant found in childhood does not usually lead to cancer.

Gene changes

Urachal cancers share many gene changes with bowel (colorectal) cancers, such as TP53 and KRAS mutations (Reis et al., 2018). Some tumours have changes in EGFR or other genes that might be targeted by drugs in future.

Other urachal conditions

Most problems with the urachus are not cancer. Benign urachal remnants are found mainly in babies and children, and they are treated differently:

Condition What it is Usual features
Patent urachus The tube stays open from bladder to belly button Urine leaks from the belly button in a newborn
Urachal cyst A closed, fluid-filled pocket along the urachus Often found by chance; may become infected
Urachal sinus Opens at the belly button only Discharge or infection at the belly button
Urachal diverticulum A pouch at the top of the bladder Usually no symptoms

Benign remnants that cause symptoms are usually removed by surgery. A remnant found in an adult may also be removed, partly because of the small risk of cancer developing later (Ashley et al., 2007).

3. Types of urachal tumour

Type Notes
Mucinous adenocarcinoma Most common; produces a lot of mucus
Enteric (intestinal-type) adenocarcinoma Looks like bowel cancer
Signet-ring cell adenocarcinoma Cells filled with mucus; more aggressive
Mixed types Combination of patterns
Mucinous cystic tumours Range from non-invasive tumours to invasive cancer
Non-glandular cancers Urothelial, squamous or small cell; rare

Pathologists use international criteria to decide whether a bladder adenocarcinoma is truly urachal (Reis et al., 2025). Key features include a tumour in the dome or front wall of the bladder, a sharp boundary between tumour and normal bladder lining, and no bowel cancer elsewhere.

4. How does it look

On scans

Scan Typical appearance
CT scan A mass in the midline, at the top of the bladder, often extending upwards towards the belly button
Calcification Specks of calcium within the tumour, seen in many cases and a helpful clue
MRI scan Shows the mucus-rich tumour and its relationship to the bladder and abdominal wall
PET-CT May be used to look for spread

On cystoscopy

During cystoscopy, a camera test of the bladder, the tumour usually appears at the dome of the bladder. It may look like a raised lump or ulcer, sometimes with mucus coming from it. Because much of the tumour lies outside the bladder wall, the inside of the bladder can look surprisingly normal.

Visible signs

Sign What it looks like
Blood in the urine Pink, red or brown urine
Mucus in the urine Cloudy urine with jelly-like strands
Lump below the belly button A firm swelling in the lower abdomen
Discharge from the belly button Rare; blood, mucus or pus

Under the microscope

Most tumours are glandular, with mucus-producing cells. Many look very similar to bowel adenocarcinoma, so doctors check the bowel to make sure the cancer has not spread from there.

5. Symptoms

Common symptoms

  • Blood in the urine (haematuria), the most common symptom
  • Mucus in the urine (mucusuria), which is unusual and an important clue
  • Pain in the lower abdomen
  • A lump between the bladder and belly button
  • Pain or burning when passing urine
  • Needing to pass urine more often or urgently
  • Repeated urinary infections

Symptoms of advanced disease

  • Swollen abdomen, which may be caused by mucus-producing deposits in the abdomen
  • Weight loss and tiredness
  • Bone pain or breathlessness, if the cancer has spread

When to seek medical advice

See a doctor promptly if you notice blood in your urine, even once. Also seek advice if your urine contains jelly-like mucus or you notice a lump in the lower abdomen.

Blood in the urine has many causes, most of them not cancer, but it always needs checking.

6. Diagnosis

Test Purpose
Urine tests Check for blood, infection and abnormal cells
Cystoscopy Looks inside the bladder
Biopsy or transurethral resection Removes tissue for diagnosis
CT or MRI of the abdomen and pelvis Shows the size and spread of the tumour
CT of the chest Checks the lungs
Colonoscopy Rules out a bowel cancer that has spread to the bladder
Tumour markers CEA, CA19-9 and CA125 are raised in many patients and can help with follow-up (Stokkel et al., 2023)

Staging

Two staging systems are commonly used for urachal carcinoma (Ashley et al., 2006; Molina et al., 2007):

Mayo stage Description
I Confined to the urachus and bladder
II Extends beyond the muscle layer of the urachus or bladder
III Spread to local lymph nodes
IV Spread to distant organs, such as the lungs, bones or liver, or to non-regional lymph nodes

The older Sheldon system divides tumours into stages I to IV with sub-stages and is still used in some reports (Sheldon et al., 1984).

7. Treatment

Urachal carcinoma should be treated in a specialist urology cancer centre. Because it behaves like a bowel cancer, colorectal oncologists are often involved in planning chemotherapy.

Surgery

The standard treatment for localised disease is en bloc surgery, meaning the tumour is removed in one piece together with the surrounding tissue:

Part removed Why
Partial cystectomy Removes the top of the bladder, including the tumour, with a margin of healthy tissue
Urachus and median umbilical ligament Removes the whole urachal remnant where cancer can spread
Belly button (umbilicus) Reduces the risk of the cancer returning
Pelvic lymph nodes To check for spread and guide treatment

Partial cystectomy keeps most of the bladder, so most people pass urine normally afterwards. Radical cystectomy, removal of the whole bladder, is needed only when the tumour is very large or involves other parts of the bladder.

The operation can be done as open, laparoscopic or robot-assisted surgery (Stokkel et al., 2022).

Chemotherapy

Situation Typical approach
After surgery Sometimes considered for high-risk disease, though benefit is not proven
Advanced or spread disease Fluorouracil-based combinations, often with oxaliplatin or cisplatin, similar to bowel cancer treatment (Siefker-Radtke et al., 2003)
Further lines Other bowel-cancer drugs or clinical trials

Other treatments

Treatment Role
Radiotherapy Mainly to control symptoms such as bleeding or pain
Surgery for peritoneal spread Cytoreductive surgery with heated chemotherapy (HIPEC) in selected patients
Targeted drugs and immunotherapy Studied in selected patients with matching gene changes

8. Outlook (prognosis)

Overall, about half of people with urachal carcinoma are alive 5 years after diagnosis (Szarvas et al., 2016). The outlook depends mainly on stage and on whether the surgeon can remove the cancer with clear margins.

Factor Effect
Cancer confined to the urachus and bladder Good outlook after surgery
Clear surgical margins and removal of the umbilicus Lower risk of return
Lymph node or distant spread Poorer outlook
Signet-ring cell type May be linked with poorer outcomes
Raised tumour markers that fall after surgery Useful for monitoring

Recovery after surgery

Stage What to expect
In hospital Usually 3-7 days; a catheter drains the bladder while it heals
Catheter Often stays in for 1-2 weeks; a bladder X-ray may check for leaks before removal
First weeks at home Tiredness, a frequent need to pass urine and some discomfort around the wound
Return to normal activity Usually within 4-8 weeks; heavy lifting is avoided for about 6 weeks
Bladder capacity The bladder usually stretches again over several months

9. Follow-up

After treatment, follow-up usually includes cystoscopy, CT scans and tumour marker blood tests. These are done every few months for the first 2-3 years, then less often. Most relapses happen within the first few years, often in the pelvis, abdominal lining, lungs or bones.

10. Living with urachal carcinoma

  • Ask about recovery time after surgery; most people return to normal activities within 4-8 weeks
  • Expect some bladder changes, such as passing urine more often, which usually improve
  • Report blood or mucus in the urine after treatment
  • Seek support from bladder cancer charities and specialist nurses

11. Frequently asked questions

Question Answer
Is it the same as bladder cancer? It affects the bladder but is a different disease, with a different origin and treatment
Why remove my belly button? The urachus runs up to the belly button, and removing it reduces the risk of the cancer returning
Will I keep my bladder? Most people have partial cystectomy and keep most of their bladder
Is it inherited? No
Does chemotherapy work? Bowel-cancer-type chemotherapy can shrink advanced disease in some people
Why do I need a colonoscopy? Bowel cancer can spread to the bladder and look very similar, so it must be ruled out
Will I need a urine bag? Rarely. Only people who need the whole bladder removed need a new way of passing urine

12. Questions to ask your care team

  • Is my cancer confined to the urachus and bladder?
  • Will I have partial or complete removal of the bladder?
  • Will my belly button and lymph nodes be removed?
  • Will I need chemotherapy?
  • Which tumour markers will be used to monitor me?
  • How often will I have scans and cystoscopy after treatment?

Resources

  1. Szarvas, T. et al. (2016) ‘Clinical, prognostic, and therapeutic aspects of urachal carcinoma – a comprehensive review with meta-analysis of 1,010 cases’, Urologic Oncology, 34(9), pp. 388-398.
  2. Ashley, R.A. et al. (2006) ‘Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy’, Cancer, 107(4), pp. 712-720.
  3. Molina, J.R. et al. (2007) ‘Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases’, Cancer, 110(11), pp. 2434-2440.
  4. Siefker-Radtke, A.O. et al. (2003) ‘Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience’, Journal of Urology, 169(4), pp. 1295-1298.
  5. Sheldon, C.A. et al. (1984) ‘Malignant urachal lesions’, Journal of Urology, 131(1), pp. 1-8.
  6. Reis, H. et al. (2018) ‘Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas’, International Journal of Cancer, 143(7), pp. 1764-1773.
  7. Reis, H. et al. (2025) ‘The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on best practice recommendations on the pathology of urachal neoplasms’, American Journal of Surgical Pathology, 49(11), pp. e18-e26.
  8. Olah, C. et al. (2024) ‘Estimation of the incidence of urachal cancer: a systematic review and meta-analysis of registry-based studies’, Urologic Oncology, 42(7), pp. 221.e1-221.e7.
  9. Stokkel, L.E. et al. (2023) ‘Clinical value of preoperative serum tumor markers CEA, CA19-9, CA125, and CA15-3 in surgically treated urachal cancer’, Urologic Oncology, 41(7), pp. 326.e17-326.e24.
  10. Stokkel, L.E. et al. (2022) ‘Robot-assisted partial cystectomy versus open partial cystectomy for patients with urachal cancer’, Urologia Internationalis, 106(8), pp. 840-847.
  11. Ashley, R.A. et al. (2007) ‘Urachal anomalies: a longitudinal study of urachal remnants in children and adults’, Journal of Urology, 178(4 Pt 2), pp. 1615-1618.

Prepared by the editorial team, October 2026.